Document is current
Any future updates will be listed below
-
Authors
Sedrak, Mina S.
Sun, Can-Lan
Bae, Marie
Freedman, Rachel A.
Magnuson, Allison
O’Connor, Tracey
Moy, Beverly
Wildes, Tanya M.
Klepin, Heidi D.
Chapman, Andrew E.
Tew, William P.
Dotan, Efrat
Fenton, Mary Anne
Kim, Heeyoung
Katheria, Vani
Muss, Hyman B.
Cohen, Harvey J.
Gross, Cary P.
Ji, Jingran
-
Funding
Funding for this research was provided by:
COH Cancer Control and Population Sciences Pilot Award
Waisman Innovation Award
National Institute on Aging (K76 AG074918, K76 AG064394, K23 AG038361)
National Cancer Institute (R21 CA277660, P30 CA008748)
American Cancer Society (125912-MRSG-14-240-01-CPPB)
Susan G. Komen for the Cure (CCR14298143)
Conquer Cancer Foundation (2023YIA-3100001264)
- License Information
-
More Information
Article History
Received: 3 October 2023
Accepted: 4 April 2024
First Online: 28 April 2024
Declarations
:
: The authors declare no competing interests.
: Dr. Sedrak reports institutional funding for research from Novartis, Seattle Genetics, Eli Lilly, and Pfizer. Dr. Freedman reports institutional funding for research from Puma Biotechnology. Dr. O’Connor reports an Advisory Board role for Amgen. Dr. Klepin reports royalties from UpToDate. Dr. Dotan reports research grant support from NCCN/Lilly; institutional funding for research from, Astra Zeneca, Incyte, MedImmune, Relay, Kinate, Lutris, Gilead, Ipsen; Honoraria/Advisory board from Pfizer, Incyte, Taiho, G1 Therapeutics and Olympus. Dr. Gross reports research funding from NCCN/Astra Zeneca, Johnson & Johnson, and Genentech. The authors report no other disclosures.
